Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

GLP-1 receptor agonists: an updated review of head-to-head clinical studies

Open access
Trujillo, Jennifer M., Nuffer, Wesley, Smith, Brooke A. · 2021 · Therapeutic Advances in Endocrinology and Metabolism

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while having a low risk of hypoglycemia. Some also have documented cardiovascular benefit. The GLP-1 RA class has grown in the last decade, with several agents available for use in the United States and Europe. Since the efficacy and tolerability, dosing frequency, administration requirements, and cost may vary between agents within the class, each agent may offer unique advantages and disadvantages. Through a review of phase III clinical trials studying dulaglutide, exenatide twice daily, exenatide once weekly, liraglutide, lixisenatide, semaglutide, and oral semaglutide, 14 head-to-head trials were identified that evaluated the safety and efficacy of GLP-1 RA active comparators. The purpose of this review is to provide an analysis of these trials. The GLP-1 RA head-to-head clinical studies have demonstrated that all GLP-1 RA agents are effective therapeutic options at reducing A1C. However, differences exist in terms of magnitude of effect on A1C and weight as well as frequency of adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2042018821997320

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Changes in A1C values with GLP-1 RAs in head-to-head clinical studies. *p < 0.05. +p < 0.05 for a pre-defined non-inferiority margin. A1C, hemoglobin A1C; GLP-1 RA, glucagon-like peptide-1 receptor agonists.
Figure 1. Changes in A1C values with GLP-1 RAs in head-to-head clinical studies. *p < 0.05. +p < 0.05 for a pre-defined non-inferiority margin. A1C, hemoglobin A1C; GLP-1 RA, glucagon-like peptide-1 receptor agonists.CC BY-NC · PubMed Central
Figure 2. Changes in weight with GLP-1 RAs in head-to-head clinical studies. *p < 0.05 GLP-1 RA, glucagon-like peptide-1 receptor agonists.
Figure 2. Changes in weight with GLP-1 RAs in head-to-head clinical studies. *p < 0.05 GLP-1 RA, glucagon-like peptide-1 receptor agonists.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Mody R, Paper presented virtually at the 80th American Diabetes Association Scientific Sessions

Cited by

See all 289

Metadata

Authors
Trujillo, J. M., Nuffer, W., & Smith, B. A.
Affiliations
  • University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Mail Stop C238, 12850 E. Montview Blvd., V20-1222, Aurora, CO 80045, USA
  • University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA
Corresponding author
Trujillo, Jennifer M.
Venue
Therapeutic Advances in Endocrinology and Metabolism
Published
2021-01
Volume
12
Pages
2042018821997320-2042018821997320
ISSN
  • 2042-0188 (ISSN-L)
  • 2042-0196
OpenAlex
W3134100899
Cited by
289
References
27
Citations by year
2026: 43 · 2025: 60 · 2024: 66 · 2023: 65 · 2022: 46 · 2021: 9
FWCI
7.14
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Endocrinology and Metabolism (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, dulaglutide, exenatide twice daily, exenatide once weekly, liraglutide, lixisenatide, semaglutide, oral semaglutide, weight loss, adverse effects, cardiovascular benefits, drug efficacy and tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 receptor agonists: an updated review of head-to-head clinical studies. https://app.cochat.ai/papers/10.1177/2042018821997320
The paper
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021). GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/2042018821997320

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.